Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention

BACKGROUND: Prasugrel is recommended over clopidogrel in poor/intermediate CYP2C19 metabolizers with acute coronary syndrome (ACS) and planned percutaneous coronary intervention (PCI), reducing the risk of ischemic events. CYP2C19 genetic testing can guide antiplatelet therapy in ACS patients. OBJEC...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Vardhaman, Lin, Fang-Ju, Ojo, Olaitan, Rao, Sapna, Yu, Shengsheng, Zhan, Lin, Touchette, Daniel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centro de Investigaciones y Publicaciones Farmaceuticas 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161409/
https://www.ncbi.nlm.nih.gov/pubmed/25243032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161409/
https://www.ncbi.nlm.nih.gov/pubmed/25243032

Ejemplares similares